Which EGFR mutation types are specifically suitable for Lazertinib?

Lazertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) specifically designed to treat patients with non-small cell lung cancer (NSCLC) who carry specific EGFR mutations. It is highly targeted and can effectively inhibit EGFR sensitive mutations and drug-resistant mutations. It is especially outstanding in overcoming the drug resistance caused by the T790M mutation and has become an important clinically important targeted therapy drug.

Specifically, lanzutinib is mainly suitable for patients carrying EGFR sensitive mutations, including 19 exon deletions (Exon 19 deletion) and 21 exon L858R point mutation, these two mutations are The most common type of driver mutation in NSCLC accounts for more than 85%of EGFR mutations. Targeting these mutations, Lanzertinib can effectively block the signal transduction of tumor cells and inhibit tumor proliferation.

In addition, lanzutinib is particularly suitable for patients who develop the T790M resistance mutation after receiving first- or second-generation EGFR inhibitors. T790M mutation is the main mechanism of drug resistance in EGFR mutated lung cancer. Lanzertinib has strong selectivity and can effectively target and inhibit the T790M mutation to help patients delay disease progression.

In short, Lanzertinib is suitable for patients with EGFR sensitive mutations (19 exon deletion, Non-small cell lung cancer patients with exon 21L858R) and acquired drug resistance mutation T790M. Its good efficacy and tolerability make it an important choice for the treatment of patients with EGFR mutation-positive lung cancer. Patients should confirm their mutation type through genetic testing before taking the drug to formulate the best individualized treatment plan.

Reference materials:https://www.drugs.com

xa0